

# AlphaLISA® CXCL4/PF4 (Human) Detection Kit

Product number: AL398 HV/C/F

Research Use Only. Not for use in diagnostic procedures.

### **Product Information**

**Application:** This kit is designed for the quantitative determination of CXCL4/PF4 in human serum,

plasma, and cell culture supernatants using a homogeneous AlphaLISA assay (no wash steps). The assay shows minumum cross-reactivity with mouse CXCL4/PF4

and human CXCL4L1/PF4V.

Sensitivity: Lower Detection Limit (LDL): 1.3 pg/mL

Lower Limit of Quantification (LLOQ): 4.3 pg/mL

EC<sub>50</sub>: 10.1 ng/mL

**Dynamic range:** 1.3 – 100,000 pg/mL




Figure 1. Typical sensitivity curve in AlphaLISA Immunoassay Buffer. The data was generated using a white Optiplate<sup>TM</sup>-384 microplate and the EnVision® Multilabel Plate Reader 2103 with Alpha option.

Storage: Store kit in the dark at +4°C. For reconstituted analyte aliquot and store at -80 °C.

Freeze-thaw cycles may impact sensitivity.

Stability: This kit is stable for at least 6 months from the manufacturing date when stored in its

original packaging and the recommended storage conditions.

### **Analyte of Interest**

Chemokine ligand 4 (CXCL4), otherwise known as platelet factor 4 (PF4) is a small 8 kDa cytokine belonging to the CXC chemokine family. During platelet aggregation, CXCL4/PF4 is released from alpha-granules of activated platelets. The active protein is a tetramer ring of PF4 subunits which binds with high affinity to heparin. The function of CXCL4/PF4 is to promote blood clotting by neutralization of the anticoagulant effect of heparin molecules, by binding them on the endothelial surface of blood vessels. Mature human CXCL4/PF4 shares 96% amino acid sequence identity with the variant CXCL4L1/PF4V and 75% with mouse CXCL4/PF4. During heparin administration, some patients generate antibodies against the CXCL4/PF4/heparin complex, which activate platelets and can cause heparin-induced thrombocytopenia (HIT) and/or arterial thrombosis. The CXCL4/PF4 AlphaLISA detection kit allows for the detection of CXCL4/PF4 in human serum, plasma, and cell culture supernatants.

### **Description of the AlphaLISA Assay**

AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm (Figure 2).




Figure 2. AlphaLISA Assay Principle.

#### **Precautions**

- The Alpha Donor beads are light-sensitive. All the other assay reagents can be used under normal light conditions. All Alpha assays using the Donor beads should be performed under subdued laboratory lighting (< 100 lux). Green filters (LEE 090 filters (preferred) or Roscolux filters #389 from Rosco) can be applied to light fixtures.
- Take precautionary measures to avoid contamination of the reagent solutions.
- The Biotinylated Anti-Analyte Antibody contains sodium azide. Contact with skin or inhalation should be avoided.

### **Kit Content: Reagents and Materials**

Kit components	AL398HV (100 assay points***)	AL398C (500 assay points***)	AL398F (5000 assay points***)
AlphaLISA Anti-CXCL4/PF4 Acceptor beads stored in PBS, 0.05% Kathon, pH 7.2	20 μL @ 5 mg/mL (1 brown tube, <u>white</u> cap)	50 μL @ 5 mg/mL (1 brown tube, <u>white</u> cap)	500 μL @ 5 mg/mL (1 brown tube, <u>white</u> cap)
Streptavidin (SA)-coated Donor beads stored in 25 mM HEPES, 100 mM NaCl, 0.05% Kathon, pH 7.4	40 μL @ 5 mg/mL (1 brown tube, <u>black</u> cap)	100 μL @ 5 mg/mL (1 brown tube, <u>black</u> cap)	1 mL @ 5 mg/mL (1 brown tube, <u>black</u> cap)
Biotinylated Anti-CXCL4/PF4 Antibody stored in PBS, 0.1% Tween-20, 0.05% NaN <sub>3</sub> , pH 7.4	20 μL @ 500 nM (1 tube, <u>black</u> cap)	50 μL @ 500 nM (1 tube, <u>black</u> cap)	500 μL @ 500 nM (1 tube, <u>black</u> cap)
Lyophilized Human CXCL4/PF4*	0.3 μg (1 tube, <u>clear</u> cap)	0.3 μg (1 tube, <u>clear</u> cap)	0.3 μg (1 tube, <u>clear</u> cap)
AlphaLISA Immunoassay Buffer (10X)**	2 mL, 1 small bottle	10 mL, 1 medium bottle	100 mL, 1 large bottle

<sup>\*</sup> Reconstitute lyophilized analyte in 100 μL Milli-Q<sup>®</sup> grade H<sub>2</sub>O. The reconstituted analyte should be used within 60 minutes or aliquoted into screw-capped polypropylene vials and stored at -80°C for further experiments. Avoid multiple freeze-thaw cycles. One vial contains an amount of analyte sufficient for performing 10 standard curves. Additional vials can be ordered separately (cat # AL398S).

Sodium azide should **not** be added to the stock reagents. High concentrations of sodium azide (> 0.001 % final in the assay) might decrease the AlphaLISA signal. Note that sodium azide from the Biotinylated Antibody stock solution will not interfere with the AlphaLISA signal (0.0001% final in the assay).

#### Specific additional required reagents and materials:

The following materials are recommended:

Item	Suggested source	Catalog #
TopSeal™-A Plus Adhesive Sealing Film	Revvity Inc.	6050185
EnVision®-Alpha Reader	Revvity Inc.	-

<sup>\*\*</sup> Extra buffer can be ordered separately (cat # AL000C: 10 mL, cat # AL000F: 100 mL).

<sup>\*\*\*</sup> The number of assay points is based on an assay volume of 100  $\mu$ L in 96-well plates or 50  $\mu$ L in 96- or 384-well assay plates using the kit components at the recommended concentrations.

#### Recommendations

- The volume indicated on each tube is guaranteed for single pipetting. Multiple pipetting of the reagents may reduce the theoretical amount left in the tube. To minimize loss when pipetting beads, it is preferable not to pre-wet the tip.
- Centrifuge all tubes (including lyophilized analyte) before use to improve recovery of content (2000g, 10-15 sec). Re-suspend all reagents by vortexing before use.
- Use Milli-Q® grade H<sub>2</sub>O (18 MΩ•cm) to dilute 10X AlphaLISA Immunoassay Buffer and to reconstitute the lyophilized analyte.
- When diluting the standard or samples, <u>change tips</u> between each standard or sample dilution. When loading reagents in the assay microplate, <u>change tips</u> between each standard or sample addition and after each set of reagents.
- When reagents are added to the microplate, make sure the liquids are at the bottom of the well.
- Small volumes may be prone to evaporation. It is recommended to cover microplates with TopSeal-A
  Adhesive Sealing Films to reduce evaporation during incubation. Microplates can be read with the
  TopSeal-A Film.
- The AlphaLISA signal is detected with an EnVision Multilabel Reader equipped with the Alpha option using the AlphaScreen standard settings (e.g. Total Measurement Time: 550 ms, Laser 680 nm Excitation Time: 180 ms, Mirror: D640as, Emission Filter: M570w, Center Wavelength 570 nm, Bandwidth 100 nm, Transmittance 75%).
- AlphaLISA signal will vary with temperature and incubation time. For consistent results, identical incubation times and temperature should be used for each plate.
- The standard curves shown in this technical data sheet are provided for information only. A standard curve must be generated for each experiment.

### **Assay Procedure**

### IMPORTANT: PLEASE READ THE RECOMMENDATIONS BELOW BEFORE USE

- The manual described below is an example for generating one standard curve in a 50 µL final assay volume (48 wells, triplicate determinations). The manuals also include testing samples in 452 wells. If a different amount of samples are tested, the volumes of all reagents have to be adjusted accordingly, as shown in the table below. These calculations do not include excess reagent to account for losses during transfer of solutions or dead volumes.
- The standard dilution manual is provided for information only. As needed, the number of replicates or the range of concentrations covered can be modified.
- Use of four background points in triplicate (12 wells) is recommended when LDL/LLOQ is calculated. One background point in triplicate (3 wells) can be used when LDL/LLOQ is not calculated.


				Volume			
Format	# of data points	Final	Sample	AlphaLISA Acceptor beads and	Biotinylated Antibody	SA-Donor beads	Plate recommendation
AL398HV	100	100 µL	10 µL	20 μL	20 μL	50µL	White OptiPlate-96 (cat # 6005290) White ½ AreaPlate-96 (cat # 6005560)
	250	100 µL	10 µL	20 μL	20 μL	50 μL	White OptiPlate-96 (cat # 6005290) White ½ AreaPlate-96 (cat # 6005560)
AL398C	500	50 µL	5 μL	10 μL	10 μL	25 μL	White ½ AreaPlate-96 (cat # 6005560) White OptiPlate-384 cat # 6007290) Light gray AlphaPlate™-384 (cat # 6005350)
	1 250	20 µL	2 μL	4 µL	4 μL	10 μL	Light gray AlphaPlate-384 (cat # 6005350) ProxiPlate™-384 Plus (cat # 6008280) White OptiPlate-384 (cat # 6007290)
	2 500	10 μL	1 µL	2 µL	2 μL	5 μL	Light gray AlphaPlate-1536 (cat # 6004350)
	5 000	50 μL	5 μL	10 μL	10 μL	25 µL	White ½ AreaPlate-96 (cat # 6005560) White OptiPlate-384 (cat # 6007290) Light gray AlphaPlate-384 (cat # 6005350)
AL398F	12 500	20 µL	2 μL	4 µL	4 µL	10 μL	Light gray AlphaPlate-384 (cat # 6005350) ProxiPlate-384 Plus (cat # 6008280) White OptiPlate-384 (cat # 6007290)
	25 000	10 µL	1 µL	2 μL	2 μL	5 μL	Light gray AlphaPlate-1536 (cat # 6004350)

- 3 Step Manual described below is for 500 assay points including one standard curve (48 wells) and samples (452 wells). If a different amount of samples are tested, the volumes of all reagents have to be adjusted accordingly.
- Preparation of 1X AlphaLISA Immunoassay Buffer: Add 5 mL of 10X AlphaLISA Immunoassay Buffer to 45 mL Milli-Q<sup>®</sup> grade H<sub>2</sub>O.
- 2) Preparation of CXCL4/PF4 analyte standard dilutions:
  - a. Reconstitute 0.3 μg lyophilized CXCL4/PF4 with 100 μL Milli-Q® grade H<sub>2</sub>O.
  - b. <u>Prepare</u> standard dilutions as follows in 1X AlphaLISA Immunoassay Buffer (change tip between each standard dilution):

Tuba	Vol. of CXCL4/PF4	Vol. of	[CXCL4/PF4] in standard curve		
Tube	(µL)	diluent (µL)*	(g/mL in 5 μL)	(pg/mL in 5 µL)	
А	10 µL of reconstituted CXCL4/PF4	90	3.00E-07	300,000	
В	60 μL of tube A	120	1.00E-07	100,000	
С	60 μL of tube B	140	3.00E-08	30,000	
D	60 μL of tube C	120	1.00E-08	10,000	
E	60 μL of tube D	140	3.00E-09	3,000	
F	60 μL of tube E	120	1.00E-09	1,000	
G	60 μL of tube F	140	3.00E-10	300	
Н	60 μL of tube G	120	1.00E-10	100	
I	60 μL of tube H	140	3.00E-11	30	
J	60 μL of tube I	120	1.00E-11	10	
K	60 μL of tube J	140	3.00E-12	3	
L	60 μL of tube K	120	1.00E-12	1	
M ** (background)	0	100	0	0	
N ** (background)	0	100	0	0	
O ** (background)	0	100	0	0	
P ** (background)	0	100	0	0	

- \* Dilute standards in diluent (e.g. 1X AlphaLISA Immunoassay Buffer). At low concentrations of analyte, a significant amount of analyte can bind to the vial. Therefore, load the analyte standard dilutions in the assay microplate within 60 minutes of preparation.
- \*\* Four background points in triplicate (12 wells) are used when LDL is calculated. If LDL does not need to be calculated, one background point in triplicate can be used (3 wells).
- 3) Preparation of 5X Anti-CXCL4/PF4 AlphaLISA Acceptor beads (50 µg/mL)
  - a. Prepare just before use.
  - b. Add 50 μL of 5 mg/mL AlphaLISA Anti-CXCL4/PF4 Acceptor beads to 4950 μL 1X AlphaLISA Immunoassay buffer
- 4) Preparation of 5X Biotinylated Anti-CXCL4/PF4 Antibody (5 nM)
  - a. Prepare just before use.
  - b. Add 50 μL of 500 nM biotinylated Anti-CXCL4/PF4 antibody to 4950 μL of 1X AlphaLISA Immunoassay Buffer.
- 5) Preparation of 2X Streptavidin (SA) Donor beads (40 µg/mL):
  - a. Prepare just before use.
  - b. Keep the beads under subdued laboratory lighting.
  - c. Add 100 µL of 5 mg/mL SA-Donor beads to 12,400 µL of 1X AlphaLISA Immunoassay Buffer.

6) In a white Optiplate (384 wells):



### **Data Analysis**

- Calculate the average count value for the background wells.
- Generate a standard curve by plotting the AlphaLISA counts versus the concentration of analyte. A log scale can be used for either or both axes. No additional data transformation is required.
- Analyze data according to a nonlinear regression using the 4-parameter logistic equation (sigmoidal dose-response curve with variable slope) and a 1/Y² data weighting (the values at maximal concentrations of analyte after the hook point should be removed for correct analysis).
- The LDL is calculated by interpolating the average background counts (12 wells without analyte) + 3 x standard deviation value (average background counts + (3xSD)) on the standard curve.
- The LLOQ as measured here is calculated by interpolating the average background counts (12 wells without analyte) + 10 x standard deviation value (average background counts + (10xSD)) on the standard curve. Alternatively, the true LLOQ can be determined by spiking known concentrations of analyte in the matrix and measuring the percent recovery, and then determining the minimal amount of spiked analyte that can be quantified within a given limit (usually +/- 20% or 30% of the real concentration).
- Read from the standard curve the concentration of analyte contained in the samples.
- If samples have been diluted, the concentration read from the standard curve must be multiplied by the dilution factor.

### **Assay Performance Characteristics**

AlphaLISA assay performance described below was determined using the 3 step manual using AlphaLISA Immunoassay Buffer (IAB).

#### Assay Sensitivity:

The LDL was calculated as described above. The values correspond to the lowest concentration of analyte that can be detected in a volume of  $5 \mu L$  using the recommended assay conditions.

LDL (pg/mL)	Buffer *	# of experiments
1.27	IAB	6
3.38	DMEM	6
37.46	RPMI	6

<sup>\*</sup> The standard was prepared in these diluents and all other components were diluted in IAB. Note that LDL can be decreased (i.e. sensitivity increased) by increasing the volume of analyte in the assay (e.g. use 10  $\mu$ L of analyte in a final assay volume of 50  $\mu$ L).

### Assay Precision:

The following assay precision data were calculated from the three independent assays using two different kit lots. In each lot, the analytes were prepared in IAB, DMEM or RPMI supplemented with 10% FBS. All other components were prepared in IAB. Each assay consisted of one standard curve comprising 12 data points (each in triplicate) and 12 background wells (no analytes). The assays were performed in 384-well format.

### Intra-assay precision:

The intra-assay precision was determined by averaging 6 experiments each with 12 independent determinations in triplicate. Shown as CV%.

CXCL4/PF4	IAB	DMEM	RPMI
CV (%)	5	6	9

#### • Inter-assay precision:

The inter-assay precision was determined comparing 6 experiments each with 12 independent determinations in triplicate. Shown as CV%.

CXCL4/PF4	IAB	DMEM	RPMI
CV (%)	6	7	13

### • Spike Recovery:

Known concentrations of analyte were spiked into IAB, or in cell culture media. All samples, including non-spiked buffer or media were measured in the assay. The average recovery from three independent measurements is reported. Note that the standard curves were prepared in IAB, DMEM, and RPMI. All other components were diluted in IAB.

Spiked	% Recovery		
CXCL4/PF4 (pg/mL)	IAB	DMEM	RPMI
1000	104	99	99
300	104	98	97
100	103	103	103

### • Specificity:

Cross-reactivity of the human CXCL4/PF4 AlphaLISA Kit was tested using the following proteins at 1 ng/mL in AlphaLISA Immunoassay Buffer.

Protein	% Cross-reactivity
Human CXCL4L1/PFV4	14.9
Mouse CXCL4/PF4	0
Human CXCL10/IP-10	0
Human CXCL1/GROα	0
Human IL-8	0

#### Human Serum and Plasma Experiments


To validate the assay kit, commercially available human serum and plasma with unknown concentrations of CXCL4/PF4 was used to examine dilution linearity. Human CXCL4/PF4 was detected in both human serum and plasma samples. A human serum sample was diluted 1000 fold prior to serial dilution, and a human plasma sample was diluted 100 fold prior to serial dilution. Good dilution linearity is observed when a serum sample is diluted more than 2000 fold, and when a human plasma sample is diluted more than 400 fold.

Dilution Factor	CXCL4/PF4 De	tected (ng/mL)
	Serum	Plasma
1	17,629	201
2	16,909	262
4	16,042	298
8	17,225	340
16	17,522	367
32	17,641	391
64	17,285	386

## **Troubleshooting Guide**

You will find detailed recommendations for common situations you might encounter with your AlphaLISA Assay kit at: <a href="https://www.revvity.com">www.revvity.com</a>

RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES.



The information provided in this document is for reference purposes only and may not be all-inclusive. Revvity, Inc., its subsidiaries, and/or affiliates (collectively, "Revvity") do not assume liability for the accuracy or completeness of the information contained herein. Users should exercise caution when handling materials as they may present unknown hazards. Revvity shall not be liable for any damages or losses resulting from handling or contact with the product, as Revvity cannot control actual methods, volumes, or conditions of use. Users are responsible for ensuring the product's suitability for their specific application. REVVITY EXPRESSLY DISCLAIMS ALL WARRANTIES, INCLUDING WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, REGARDLESS OF WHETHER ORAL OR WRITTEN, EXPRESS OR IMPLIED, ALLEGEDLY ARISING FROM ANY USAGE OF ANY TRADE OR ANY COURSE OF DEALING, IN CONNECTION WITH THE USE OF INFORMATION CONTAINED HEREIN OR THE PRODUCT ITSELF

www.revvity.com

